BridgeBio Pharma, Inc. reports results for the quarter ended September 30 - Earnings Summary

• BridgeBio Pharma, Inc. reported a quarterly adjusted loss of 42 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -95 cents. The mean expectation of twenty one analysts for the quarter was for a loss of 58 cents per share. Wall Street expected results to range from -81 cents to -28 cents per share.

• Revenue rose 192.6% to $353.17 million from a year ago; analysts expected $288.05 million.

• BridgeBio Pharma, Inc.'s reported EPS for the quarter was a loss of 42 cents​.

• The company reported a quarterly loss of $56.71 million.

• BridgeBio Pharma, Inc. shares had risen by 7.6% this quarter and lost 7.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 19.8% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for BridgeBio Pharma, Inc. is $108.50, about 34.8% above its last closing price of $70.73

This summary was machine generated from LSEG data October 29 at 10:19 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)